IRLAB Therapeutics AB (OSTO:IRLAB A) Additional Paid-In Capital : kr690.21 Mil(As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is IRLAB Therapeutics AB Additional Paid-In Capital?

IRLAB Therapeutics AB's quarterly additional paid-in capital increased from Sep. 2023 (kr690.20 Mil) to Dec. 2023 (kr690.21 Mil) but then stayed the same from Dec. 2023 (kr690.21 Mil) to Mar. 2024 (kr690.21 Mil).

IRLAB Therapeutics AB's annual additional paid-in capital increased from Dec. 2021 (kr685.45 Mil) to Dec. 2022 (kr690.21 Mil) but then stayed the same from Dec. 2022 (kr690.21 Mil) to Dec. 2023 (kr690.21 Mil).

IRLAB Therapeutics AB Additional Paid-In Capital Historical Data

The historical data trend for IRLAB Therapeutics AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRLAB Therapeutics AB Additional Paid-In Capital Chart

IRLAB Therapeutics AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

428.10

685.63

685.45

690.21

IRLAB Therapeutics AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															690.21	690.21	690.20	690.21	690.21

IRLAB Therapeutics AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

IRLAB Therapeutics AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IRLAB Therapeutics AB (OSTO:IRLAB A) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

6IRA:Germany

Address

Arvid Wallgren Backe 20, Goteborg, SWE, 413 46

Website

https://www.irlab.se

IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.

IRLAB Therapeutics AB (OSTO:IRLAB A) Headlines

No Headlines